VEGF inhibition and renal thrombotic microangiopathy

Vera Eremina, J. Ashley Jefferson, Jolanta Kowalewska, Howard Hochster, Mark Haas, Joseph Weisstuch, Catherine Richardson, Jeffrey B. Kopp, M. Golam Kabir, Peter H. Backx, Hans Peter Gerber, Napoleone Ferrara, Laura Barisoni-Thomas, Charles E. Alpers, Susan E. Quaggin

Research output: Contribution to journalArticle

936 Citations (Scopus)

Abstract

The glomerular microvasculature is particularly susceptible to injury in thrombotic microangiopathy, but the mechanisms by which this occurs are unclear. We report the cases of six patients who were treated with bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), in whom glomerular disease characteristic of thrombotic microangiopathy developed. To show that local reduction of VEGF within the kidney is sufficient to trigger the pathogenesis of thrombotic microangiopathy, we used conditional gene targeting to delete VEGF from renal podocytes in adult mice; this resulted in a profound thrombotic glomerular injury. These observations provide evidence that glomerular injury in patients who are treated with bevacizumab is probably due to direct targeting of VEGF by antiangiogenic therapy.

Original languageEnglish
Pages (from-to)1129-1136
Number of pages8
JournalNew England Journal of Medicine
Volume358
Issue number11
DOIs
StatePublished - Mar 13 2008
Externally publishedYes

Fingerprint

Thrombotic Microangiopathies
Vascular Endothelial Growth Factor A
Kidney
Wounds and Injuries
Antibodies, Monoclonal, Humanized
Podocytes
Gene Targeting
Microvessels
Bevacizumab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Eremina, V., Jefferson, J. A., Kowalewska, J., Hochster, H., Haas, M., Weisstuch, J., ... Quaggin, S. E. (2008). VEGF inhibition and renal thrombotic microangiopathy. New England Journal of Medicine, 358(11), 1129-1136. https://doi.org/10.1056/NEJMoa0707330

VEGF inhibition and renal thrombotic microangiopathy. / Eremina, Vera; Jefferson, J. Ashley; Kowalewska, Jolanta; Hochster, Howard; Haas, Mark; Weisstuch, Joseph; Richardson, Catherine; Kopp, Jeffrey B.; Kabir, M. Golam; Backx, Peter H.; Gerber, Hans Peter; Ferrara, Napoleone; Barisoni-Thomas, Laura; Alpers, Charles E.; Quaggin, Susan E.

In: New England Journal of Medicine, Vol. 358, No. 11, 13.03.2008, p. 1129-1136.

Research output: Contribution to journalArticle

Eremina, V, Jefferson, JA, Kowalewska, J, Hochster, H, Haas, M, Weisstuch, J, Richardson, C, Kopp, JB, Kabir, MG, Backx, PH, Gerber, HP, Ferrara, N, Barisoni-Thomas, L, Alpers, CE & Quaggin, SE 2008, 'VEGF inhibition and renal thrombotic microangiopathy', New England Journal of Medicine, vol. 358, no. 11, pp. 1129-1136. https://doi.org/10.1056/NEJMoa0707330
Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J et al. VEGF inhibition and renal thrombotic microangiopathy. New England Journal of Medicine. 2008 Mar 13;358(11):1129-1136. https://doi.org/10.1056/NEJMoa0707330
Eremina, Vera ; Jefferson, J. Ashley ; Kowalewska, Jolanta ; Hochster, Howard ; Haas, Mark ; Weisstuch, Joseph ; Richardson, Catherine ; Kopp, Jeffrey B. ; Kabir, M. Golam ; Backx, Peter H. ; Gerber, Hans Peter ; Ferrara, Napoleone ; Barisoni-Thomas, Laura ; Alpers, Charles E. ; Quaggin, Susan E. / VEGF inhibition and renal thrombotic microangiopathy. In: New England Journal of Medicine. 2008 ; Vol. 358, No. 11. pp. 1129-1136.
@article{a050d5de61ef46d68b5b9e1a87c80704,
title = "VEGF inhibition and renal thrombotic microangiopathy",
abstract = "The glomerular microvasculature is particularly susceptible to injury in thrombotic microangiopathy, but the mechanisms by which this occurs are unclear. We report the cases of six patients who were treated with bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), in whom glomerular disease characteristic of thrombotic microangiopathy developed. To show that local reduction of VEGF within the kidney is sufficient to trigger the pathogenesis of thrombotic microangiopathy, we used conditional gene targeting to delete VEGF from renal podocytes in adult mice; this resulted in a profound thrombotic glomerular injury. These observations provide evidence that glomerular injury in patients who are treated with bevacizumab is probably due to direct targeting of VEGF by antiangiogenic therapy.",
author = "Vera Eremina and Jefferson, {J. Ashley} and Jolanta Kowalewska and Howard Hochster and Mark Haas and Joseph Weisstuch and Catherine Richardson and Kopp, {Jeffrey B.} and Kabir, {M. Golam} and Backx, {Peter H.} and Gerber, {Hans Peter} and Napoleone Ferrara and Laura Barisoni-Thomas and Alpers, {Charles E.} and Quaggin, {Susan E.}",
year = "2008",
month = "3",
day = "13",
doi = "10.1056/NEJMoa0707330",
language = "English",
volume = "358",
pages = "1129--1136",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "11",

}

TY - JOUR

T1 - VEGF inhibition and renal thrombotic microangiopathy

AU - Eremina, Vera

AU - Jefferson, J. Ashley

AU - Kowalewska, Jolanta

AU - Hochster, Howard

AU - Haas, Mark

AU - Weisstuch, Joseph

AU - Richardson, Catherine

AU - Kopp, Jeffrey B.

AU - Kabir, M. Golam

AU - Backx, Peter H.

AU - Gerber, Hans Peter

AU - Ferrara, Napoleone

AU - Barisoni-Thomas, Laura

AU - Alpers, Charles E.

AU - Quaggin, Susan E.

PY - 2008/3/13

Y1 - 2008/3/13

N2 - The glomerular microvasculature is particularly susceptible to injury in thrombotic microangiopathy, but the mechanisms by which this occurs are unclear. We report the cases of six patients who were treated with bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), in whom glomerular disease characteristic of thrombotic microangiopathy developed. To show that local reduction of VEGF within the kidney is sufficient to trigger the pathogenesis of thrombotic microangiopathy, we used conditional gene targeting to delete VEGF from renal podocytes in adult mice; this resulted in a profound thrombotic glomerular injury. These observations provide evidence that glomerular injury in patients who are treated with bevacizumab is probably due to direct targeting of VEGF by antiangiogenic therapy.

AB - The glomerular microvasculature is particularly susceptible to injury in thrombotic microangiopathy, but the mechanisms by which this occurs are unclear. We report the cases of six patients who were treated with bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), in whom glomerular disease characteristic of thrombotic microangiopathy developed. To show that local reduction of VEGF within the kidney is sufficient to trigger the pathogenesis of thrombotic microangiopathy, we used conditional gene targeting to delete VEGF from renal podocytes in adult mice; this resulted in a profound thrombotic glomerular injury. These observations provide evidence that glomerular injury in patients who are treated with bevacizumab is probably due to direct targeting of VEGF by antiangiogenic therapy.

UR - http://www.scopus.com/inward/record.url?scp=40849130173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40849130173&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa0707330

DO - 10.1056/NEJMoa0707330

M3 - Article

C2 - 18337603

AN - SCOPUS:40849130173

VL - 358

SP - 1129

EP - 1136

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 11

ER -